Shortages in Snakebite Antivenom Not Anticipated for 2004 Season
May 26, 2004

VENOM ER Brings the Raw Medical Action of Drama Series ER to Animal Planet on March 30
February 27, 2004

Fougera^® Announces New Shipment of CroFab^™;Antivenom
October 15, 2003

First Supply of CroFab^™; Snakebite Antivenom Shipping This Week
March 10, 2003

New Supply of CroFab^™; Snakebite Antivenom Shipping This Week
October 21, 2002

New Supply of CroFab^™; Snakebite Antivenom Shipping This Week
August 13, 2002

New Supply of CroFab^™; Snakebite Antivenom Shipping This Week
July 29, 2002

CroFab^™; Snakebite Antivenom Is Available for Shipment Immediately
June 5, 2002

Protherics and Savage Labs Announce Potential Shortage Snakebite Antivenom
March 27, 2002

Wyeth-Ayerst Laboratories to Experience Stock Outages Of The Snakebite Treatment -Antivenin
May 10, 2001

Emergency Medicine
Promising New Antivenom Therapy Developed For Snake Bite
NewsRx.com
March 7, 2001

Savage Laboratories Launches First New Antivenom for Poisonous Snakebites In Over 50 Years
January 31, 2001

CroFab^® Crotalidae Polyvalent Immune Fab (Ovine) is indicated for the management of patients with minimal to moderate North American Crotalid envenomation (this subfamily includes rattlesnakes, cottonmouths & copperheads.)  Early use of CroFab^® (within 6 hours of snakebite) is advised to prevent clinical deterioration and the occurrence of systemic coagulation abnormalities.

Important Safety Information
The most common adverse events reported in clinical studies were mild or moderate reactions involving the skin and appendages (primarily urticaria, rash or pruritus), which occurred in 14 out of 42 patients.  Three patients experienced a serious adverse event.  Two patients had a severe allergic reaction (severe hives and a severe rash and pruritus) following treatment.  One patient had a recurrent coagulopathy due to envenomation, which required re-hospitalization and additional antivenin administration. In clinical trials, recurrent coagulopathy (the return of a coagulation abnormality after it has been successfully treated with antivenin), characterized by decreased fibrinogen, decreased platelets and elevated prothrombin time, occurred in approximately half of the patients studied. Recurrent coagulopathy may persist for one to two weeks or more.  One patient discontinued CroFab^® therapy due to an allergic reaction.  Patients with allergies to papain, chymopapain, other papaya extracts or the pineapple enzyme bromelain may also be at risk for an allergic reaction to CroFab^®.

Please click on the CroFab^® full prescribing information link at left for complete prescribing information, including events, precautions or warnings.

* © CroFab^® is manufactured by/registered trademarks of Protherics US Inc., Brentwood, TN  37027 and distributed by Savage Laboratories^®